Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Do witnesses of functional/dissociative seizures recall them accurately? A UK experimental study of semiology recall at clinically relevant time points with a pilot intervention.

Epilepsia·2026

Same author

Associations of self-esteem in people with epilepsy.

Epilepsy & behavior : E&B·2026

Same author

Seizure duration in functional/dissociative seizures: measurement, variability and diagnostic significance.

Seizure·2026

Same author

Response of the ILAE FDS task force to: A call for reflection on unintended consequences: Should 'Functional/Dissociative Seizures' replace 'Psychogenic Nonepileptic Seizures'?

Seizure·2026

Same author

Endovascular management of craniospinal arteriovenous fistula causing steal syndrome in neurofibromatosis type 1: a case report.

AME case reports·2026

Same author

Mortality in functional seizures: Evidence from a large electronic health records dataset.

Epilepsia·2026

Search research articles

Related Experiment Videos

Presumed topiramate-induced maculopathy.

Stefan Beyenburg¹, Christophe Weyland, Markus Reuber

¹Service de Neurologie, Centre Hospitalier de Luxembourg, Rue Barblé 4, L-1210 Luxembourg, Luxembourg. beyenburg.stefan@chl.lu

Epilepsy & Behavior : E&B

|January 20, 2009

Summary

Topiramate (TPM) may cause vision loss in epilepsy patients. This case suggests TPM can induce maculopathy, potentially leading to lasting vision impairment, even after drug discontinuation.

Related Experiment Videos

Area of Science:

Ophthalmology
Neuropharmacology
Clinical Neurology

Background:

Topiramate (TPM) is a widely used antiepileptic drug.
Symptomatic epilepsy requires long-term pharmacotherapy.
Ocular side effects of some antiepileptics are known.

Observation:

A patient on TPM for epilepsy developed decreased visual acuity.
Ophthalmological evaluation indicated maculopathy.
Vision did not recover substantially after discontinuing TPM.

Findings:

The patient's maculopathy is hypothesized to be induced by TPM.
This suggests a potential retinal toxicity associated with TPM.
The visual impairment may persist despite drug cessation.

Implications:

Topiramate may pose a risk of persistent retinal toxicity.
Clinicians should monitor for visual disturbances in patients using TPM.
Further research into TPM-induced ocular toxicity is warranted.